It's really amazing to think about how far we've come over even the past decade in the health-care arena.
Keep Reading →
September 23 - News - Comments
There are few, if any, businesses in the world where innovation isn't the top priority.
Keep Reading →
September 14 - News - Comments
Yesterday, shareholders in chipmaker Advanced Micro Devices, Inc. (NYSE:AMD) and defense contractor SAIC, Inc. (NYSE:SAI) got what seemed like bad news.
Keep Reading →
September 13 - News - Comments
One of the company's ushering in the next generation of hepatitis-C treatment is Gilead Sciences, Inc. (NASDAQ:GILD).
Keep Reading →
August 28 - News - Comments
In after hours trading on April 18, a few hours after the release of my previous article focusing on Exelixis, Inc.
Keep Reading →
August 23 - News - Comments
If you've ever taken the time to really follow the biopharmaceutical sector, you know very well that failures are a dime a dozen, and success stories are few and far between.
Keep Reading →
August 19 - News - Comments
The S&P 500 includes 500 of the biggest stocks in the market.
Keep Reading →
August 5 - News - Comments
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Keep Reading →
August 1 - News - Comments
Cystic fibrosis (CF), a genetic disorder that affects the lungs, the pancreas, liver, and intestine, is the second most common inherited disorder in the United States, after sickle...
Keep Reading →
August 1 - News - Comments
With the SPDR S&P Biotech Index up 29% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
July 29 - News - Comments
Biotechnology stocks are usually valued on the potential of their pipelines, especially if there is no drug already in the market.
Keep Reading →
July 29 - News - Comments
Gilead Sciences, Inc. (NASDAQ:GILD)' shares surged over 5% in after-hours trading on Thursday after the company announced its second-quarter earnings before giving up some of...
Keep Reading →
July 29 - News - Comments
Johnson & Johnson (NYSE:JNJ) reported its second quarter on Tuesday, and turned in some positive numbers. Revenue grew 8.5%, year-over-year, up to $17.9 billion.
Keep Reading →
July 19 - News - Comments
To prove my point, I looked at the multi-year chart and picked out some of the peaks.
Keep Reading →
July 1 - News - Comments
When the stock price of a company increases significantly, investors are curious to know whether it is likely to increase further.
Keep Reading →
June 27 - News - Comments
Hepatitis-C is a contagious virus that attacks the liver and can be found in acute or chronic forms.
Keep Reading →
June 24 - News - Comments
Our job here is to examine companies through an investing perspective.
Keep Reading →
June 12 - News - Comments
A recent report by EvaluatePharma claims that sales of orphan drugs -- ones that target rare diseases -- will grow at twice the rate of the overall prescription market.
Keep Reading →
May 30 - News - Comments
After a 12-week run of seeing its share price rise for the week, Johnson & Johnson (NYSE:JNJ) stock fell last week.
Keep Reading →
May 29 - News - Comments
Combining nice dividends with a growing industry that comprises roughly one-fifth of the nation's GDP should make for an attractive stock -- in theory.
Keep Reading →
May 15 - News - Comments
What's the source of your investment strategy? Many look to great investors like Warren Buffett for guidance on how to invest.
Keep Reading →
May 13 - News - Comments
Janus Fund (JANDX) bares the name of the fund family behind it. The flagship offering focuses on growth.
Keep Reading →
May 1 - Hedge Funds - Comments
Dividend stocks can be a great addition to your portfolio, especially pharmaceutical dividend stocks that offer a bit of stability in rocky times.
Keep Reading →
May 1 - News - Comments
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have appreciated significantly in 2013 so far, and it seems that the trend might continue for the rest of the year.
Keep Reading →
April 30 - News - Comments
Biotechs with market caps of a billion dollars or more are a dime a dozen. Well, actually, they're more like $12 billion or more a dozen, but you get the point.
Keep Reading →
April 23 - News - Comments
They're demanding. They take risks -- but only calculated ones. And they ask lots of penetrating questions to understand as much as possible before putting a dime on the line.
Keep Reading →
April 22 - News - Comments
As I mentioned previously in Part 1, it was an incredibly busy week for the biotech sector.
Keep Reading →
April 20 - News - Comments
There are many biotech stocks to choose from that have long-lasting value.
Keep Reading →
April 19 - News - Comments
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Keep Reading →
April 12 - News - Comments
Gilead Sciences, Inc.
Keep Reading →
April 10 - News - Comments
Johnson & Johnson (NYSE:JNJ) announced on Monday that it had received a third Breakthrough Therapy Designation for the blood cancer drug ibrutinib that it's developing with Pharmacyclics...
Keep Reading →
April 10 - News - Comments
Gilead Sciences, Inc. (NASDAQ:GILD)' sofosbuvir with Johnson & Johnson (NYSE:JNJ) and Medivir's simeprevir are a match made in heaven.
Keep Reading →
March 5 - News - Comments
In the world of biotech stocks a lot of companies are starting to incorporate Hepatitis C treatments into their pipelines.
Keep Reading →
February 25 - News - Comments
The Motley Fool's readers have spoken, and I have heeded your cries.
Keep Reading →
February 20 - News - Comments
For instance, it's hard to make money on shoo-in Food and Drug Administration approvals. The approval is already reflected in the price.
Keep Reading →
February 19 - News - Comments
The biggest biopharmaceutical companies blazed trails and lifted portfolios last year.
Keep Reading →
February 18 - News - Comments
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
February 11 - News - Comments
Gilead Sciences, Inc.
Keep Reading →
February 4 - News - Comments